CAR-T Therapy Clinical Trials

6 actively recruiting trials

No change since May 2026

Pipeline

Phase 1: 4

Top Sponsors

Sung-Soo Park2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Peking University People's Hospital1
Guangzhou Women and Children's Medical Center1
Beijing GoBroad Hospital1

Indications

Cancer4
Systemic Lupus Erythematosus (SLE)2
Lupus2
Relapsed/refractory High Grade B Cell Lymphoma1
Systemic Sclerosis (SSc)1

Other6 trials

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Phase 1

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Phase 1

Immunotherapy in Lymphoma

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Phase 1

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.